Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Income from Continuing Operations came in at 5235000000.0 in Q1 2026, down 52.4% year-on-year from 10999000000.0 in Q1 2025, and up 2.33% quarter-over-quarter from 5116000000.0 in Q4 2025.

Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 5235000000.0 for Q1 2026.

  • Income from Continuing Operations for Q1 2026 came in at 5235000000.0, down 52.4% year-over-year; the trailing twelve-month figure through Mar 2026 was 21040000000.0 (down 3.53% YoY), and the FY2025 annual result was 26804000000.0, up 90.56% from the prior year.
  • Income from Continuing Operations came in at 5235000000.0 for Q1 2026 at Johnson & Johnson, up from 5116000000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 10999000000.0 in Q1 2025 to a low of 491000000.0 in Q2 2023.
  • The 5-year median for Income from Continuing Operations is 4310000000.0 (2022), against an average of 4411647058.82.
  • Across the five-year window, Income from Continuing Operations tumbled 110.94% in 2023 and surged 762.93% in 2024, its largest moves.
  • Johnson & Johnson's Income from Continuing Operations stood at 4310000000.0 in 2022, then retreated by 4.13% to 4132000000.0 in 2023, then decreased by 16.97% to 3431000000.0 in 2024, then jumped by 49.11% to 5116000000.0 in 2025, then grew by 2.33% to 5235000000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 5235000000.0 (Q1 2026), 5116000000.0 (Q4 2025), and 5152000000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 3.30 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 5.24 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 697.00 Mn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -4.21 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 2.02 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 2.68 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 5.24 Bn
Dec 28, 2025 5.12 Bn
Sep 28, 2025 5.15 Bn
Jun 29, 2025 5.54 Bn
Mar 30, 2025 11.00 Bn
Dec 29, 2024 3.43 Bn
Sep 29, 2024 2.69 Bn
Jun 30, 2024 4.69 Bn
Mar 31, 2024 3.26 Bn
Dec 31, 2023 4.13 Bn
Oct 1, 2023 4.31 Bn
Jul 2, 2023 5.38 Bn
Apr 2, 2023 -491.00 Mn
Jan 1, 2023 2.65 Bn
Oct 2, 2022 4.31 Bn
Jul 3, 2022 4.12 Bn
Apr 3, 2022 4.49 Bn
Oct 3, 2021 3.67 Bn
Jul 4, 2021 6.28 Bn
Apr 4, 2021 6.20 Bn